Finance

Lists
600196:SHA
Shanghai Fosun Pharmaceutical (Group) Ord Shs A
CNÂ¥22.42
-0.36%
(-0.080) 1D
Sep 2, 9:56:53 AM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600196...
Open
CNÂ¥22.51
High
CNÂ¥22.53
Low
CNÂ¥22.31
Mkt. cap
54.79B
Avg. vol.
29.45M
Volume
3.92M
Dividend
1.74%
Quarterly dividend
CNÂ¥0.10
Ex-dividend date
Jul 27, 2026
P/E ratio
17.41
52-wk high
CNÂ¥33.10
52-wk low
CNÂ¥20.85
EPS
CNÂ¥1.29
Shares outstanding
2.01B
No. of employees
41K
Open
CNÂ¥22.51
High
CNÂ¥22.53
Low
CNÂ¥22.31
Mkt. cap
54.79B
Avg. vol.
29.45M
Volume
3.92M
Dividend
1.74%
Quarterly dividend
CNÂ¥0.10
Ex-dividend date
Jul 27, 2026
P/E ratio
17.41
52-wk high
CNÂ¥33.10
52-wk low
CNÂ¥20.85
EPS
CNÂ¥1.29
Shares outstanding
2.01B
No. of employees
41K
Profile
Shanghai Fosun Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company. It is mostly owned by Fosun International. As of 2018, the A shares of the company is a constituent of SSE 180 Index as well as its sub-index SSE MidCap Index. The company was ranked 1,840th in 2020 edition of the Forbes Global 2000, a list of top listed companies of the world. Wikipedia
About Shanghai Fosun Pharmaceutical (Group) Ord Shs A
CEOWen Deyong | Liu Yi
Employees40.7K
Founded1994
Headquarters-
SectorPharmaceutical industry
Websitefosunpharma.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
9.88B
12.27B
10.07B
10.37B
Cost of goods sold
5.08B
5.65B
5.07B
5.23B
Cost of revenue
5.08B
5.65B
5.07B
5.23B
Research and development expenses
1.01B
1.28B
896.79M
1.19B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.10B
4.44B
3.27B
3.35B
Operating expense
4.04B
5.92B
4.19B
4.63B
Total operating expenses
9.12B
11.57B
9.26B
9.86B
Operating income
758.38M
699.05M
813.78M
505.27M
Other non operating income
-116.85M
107.33M
2.03M
-13.28M
EBT including unusual items
1.12B
1.27B
1.36B
1.23B
EBT excluding unusual items
1.49B
1.10B
1.21B
1.07B
Income tax expense
162.98M
82.80M
277.92M
159.73M
Effective tax rate
14.57%
6.50%
20.47%
13.00%
Other operating expenses
-92.19M
117.57M
19.04M
74.01M
Net income
821.33M
847.27M
870.83M
850.64M
Net profit margin
8.31%
6.91%
8.64%
8.20%
Earnings per share
-
-
-
-
Interest and investment income
1.05B
732.13M
689.67M
938.86M
Interest expense
-321.25M
-291.32M
-296.51M
-310.88M
Net interest expenses
727.28M
440.80M
393.16M
627.98M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.39B
1.47B
1.59B
1.24B
Gain or loss from assets sale
2.12M
-69.35M
-
-195.23K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps